Skip to main content
Erschienen in: International Journal of Clinical Oncology 1/2012

01.02.2012 | Special Article

Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer

verfasst von: Toshiaki Watanabe, Michio Itabashi, Yasuhiro Shimada, Shinji Tanaka, Yoshinori Ito, Yoichi Ajioka, Tetsuya Hamaguchi, Ichinosuke Hyodo, Masahiro Igarashi, Hideyuki Ishida, Megumi Ishiguro, Yukihide Kanemitsu, Norihiro Kokudo, Kei Muro, Atsushi Ochiai, Masahiko Oguchi, Yasuo Ohkura, Yutaka Saito, Yoshiharu Sakai, Hideki Ueno, Takayuki Yoshino, Takahiro Fujimori, Nobuo Koinuma, Takayuki Morita, Genichi Nishimura, Yuh Sakata, Keiichi Takahashi, Hiroya Takiuchi, Osamu Tsuruta, Toshiharu Yamaguchi, Masahiro Yoshida, Naohiko Yamaguchi, Kenjiro Kotake, Kenichi Sugihara, Japanese Society for Cancer of the Colon and Rectum

Erschienen in: International Journal of Clinical Oncology | Ausgabe 1/2012

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer is a major cause of death in Japan, where it accounts for the largest number of deaths from malignant neoplasms in women and the third largest number in men. Many new treatment methods have been developed over the last few decades. The Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer (JSCCR Guidelines 2010) have been prepared to show standard treatment strategies for colorectal cancer, to eliminate disparities among institutions in terms of treatment, to eliminate unnecessary treatment and insufficient treatment, and to deepen mutual understanding between health-care professionals and patients by making these Guidelines available to the general public. These Guidelines have been prepared by consensuses reached by the JSCCR Guideline Committee, based on a careful review of the evidence retrieved by literature searches and in view of the medical health insurance system and actual clinical practice settings in Japan. Therefore, these Guidelines can be used as a tool for treating colorectal cancer in actual clinical practice settings. More specifically, they can be used as a guide to obtaining informed consent from patients and choosing the method of treatment for each patient. As a result of the discussions held by the Guideline Committee, controversial issues were selected as Clinical Questions, and recommendations were made. Each recommendation is accompanied by a classification of the evidence and a classification of recommendation categories based on the consensus reached by the Guideline Committee members. Here we present the English version of the JSCCR Guidelines 2010.
Fußnoten
1
In polypectomy, a snare is placed on the stalk of the lesion, and the lesion is electrocauterized using a high-frequency current. This method is mainly used for protruding lesions.
 
2
In EMR, the lesion is elevated through the local injection of a liquid such as physiological saline into the submucosa, and the lesion is electrocauterized just as in polypectomy. This method comprises the snare method [2] and EMR using a cap (EMRC). It is mainly used for superficial tumors and large sessile lesions.
 
3
In ESD, the lesion is elevated through the local injection of a liquid such as sodium hyaluronate solution into the submucosa of the perilesional area; then, circumferential incision of the mucosa surrounding the lesion and dissection of the submucosa are performed with a special knife [3]. ESD is mainly indicated for large tumors that cannot be resected by EMR.
 
4
FOLFOX is infusional 5-FU + LV + L-OHP.
 
5
CapeOX is capecitabine + L-OHP.
 
6
FOLFIRI is infusional 5-FU + LV + CPT-11.
 
Literatur
1.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum (2010) JSCCR guidelines 2010 for the treatment of colorectal cancer. Kanehara & Co., Ltd., Tokyo Japanese Society for Cancer of the Colon and Rectum (2010) JSCCR guidelines 2010 for the treatment of colorectal cancer. Kanehara & Co., Ltd., Tokyo
2.
Zurück zum Zitat Kudo S (1993) Endoscopic mucosal resection of flat and depressed early colorectal cancer. Endoscopy 25:455–461 Kudo S (1993) Endoscopic mucosal resection of flat and depressed early colorectal cancer. Endoscopy 25:455–461
3.
Zurück zum Zitat Tanaka S, Oka S, Chayama K (2008) Colorectal endoscopic submucosal dissection (ESD): the present status and future perspective including its differentiation from endoscopic mucosal resection (EMR). J Gastroenterol 43:641–651 Tanaka S, Oka S, Chayama K (2008) Colorectal endoscopic submucosal dissection (ESD): the present status and future perspective including its differentiation from endoscopic mucosal resection (EMR). J Gastroenterol 43:641–651
4.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum (2010) Multi-Institutional Registry of Large Bowel Cancer in Japan. Cases treated in 1995–1998 [vols. 17 (1999), 18 (2000), 21 (2001), 24 (2003)]. Japanese Society for Cancer of the Colon and Rectum, Tokyo Japanese Society for Cancer of the Colon and Rectum (2010) Multi-Institutional Registry of Large Bowel Cancer in Japan. Cases treated in 1995–1998 [vols. 17 (1999), 18 (2000), 21 (2001), 24 (2003)]. Japanese Society for Cancer of the Colon and Rectum, Tokyo
5.
Zurück zum Zitat Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 69:613–616CrossRefPubMed Heald RJ, Husband EM, Ryall RD (1982) The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? Br J Surg 69:613–616CrossRefPubMed
6.
Zurück zum Zitat MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. Lancet 341:457–460CrossRefPubMed MacFarlane JK, Ryall RD, Heald RJ (1993) Mesorectal excision for rectal cancer. Lancet 341:457–460CrossRefPubMed
7.
Zurück zum Zitat Enker WE, Thaler HT, Cranor ML et al (1995) Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 181:335–346PubMed Enker WE, Thaler HT, Cranor ML et al (1995) Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg 181:335–346PubMed
8.
Zurück zum Zitat Lowry AC, Simmang CL, Boulos P et al (2001) Consensus statement of definitions for anorectal physiology and rectal cancer. Dis Colon Rectum 44:915–919CrossRefPubMed Lowry AC, Simmang CL, Boulos P et al (2001) Consensus statement of definitions for anorectal physiology and rectal cancer. Dis Colon Rectum 44:915–919CrossRefPubMed
9.
Zurück zum Zitat Sugihara K, Kobayashi H, Kato T et al (2006) Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 49:1663–1672CrossRefPubMed Sugihara K, Kobayashi H, Kato T et al (2006) Indication and benefit of pelvic sidewall dissection for rectal cancer. Dis Colon Rectum 49:1663–1672CrossRefPubMed
10.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum (1998) General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 6th edn. Kanehara & Co., Ltd., Tokyo Japanese Society for Cancer of the Colon and Rectum (1998) General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 6th edn. Kanehara & Co., Ltd., Tokyo
11.
Zurück zum Zitat Mentges B, Buess G, Schafer D et al (1996) Local therapy of rectal tumors. Dis Colon Rectum 39:886–892CrossRefPubMed Mentges B, Buess G, Schafer D et al (1996) Local therapy of rectal tumors. Dis Colon Rectum 39:886–892CrossRefPubMed
12.
Zurück zum Zitat Murata S, Moriya Y, Akasu T et al (1998) Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 83:1086–1093CrossRefPubMed Murata S, Moriya Y, Akasu T et al (1998) Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma. Cancer 83:1086–1093CrossRefPubMed
13.
Zurück zum Zitat Robinson BJ, Rice TW, Strong SA et al (1999) Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 117:66–76CrossRefPubMed Robinson BJ, Rice TW, Strong SA et al (1999) Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 117:66–76CrossRefPubMed
14.
Zurück zum Zitat Lambert LA, Colacchio TA, Barth RJ Jr (2000) Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 135:473–479CrossRefPubMed Lambert LA, Colacchio TA, Barth RJ Jr (2000) Interval hepatic resection of colorectal metastases improves patient selection. Arch Surg 135:473–479CrossRefPubMed
15.
Zurück zum Zitat Kobayashi K, Kawamura M, Ishihara T (1999) Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 118:1090–1096CrossRefPubMed Kobayashi K, Kawamura M, Ishihara T (1999) Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 118:1090–1096CrossRefPubMed
16.
Zurück zum Zitat Regnard JF, Grunenwald D, Spaggiari L et al (1998) Surgical treatment for hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66:214–218CrossRefPubMed Regnard JF, Grunenwald D, Spaggiari L et al (1998) Surgical treatment for hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66:214–218CrossRefPubMed
17.
Zurück zum Zitat Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500CrossRefPubMed Patchell RA, Tibbs PA, Walsh JW et al (1990) A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322:494–500CrossRefPubMed
18.
Zurück zum Zitat National Institute of Health Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444–1450 National Institute of Health Consensus Conference (1990) Adjuvant therapy for patients with colon and rectal cancer. JAMA 264:1444–1450
19.
Zurück zum Zitat Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408CrossRefPubMed Benson AB 3rd, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408CrossRefPubMed
20.
Zurück zum Zitat Van Cutsem E, Oliveira J, ESMO Guidelines Working Group (2008) Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 19(Suppl 2):ii29–ii30 Van Cutsem E, Oliveira J, ESMO Guidelines Working Group (2008) Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up. Ann Oncol 19(Suppl 2):ii29–ii30
21.
Zurück zum Zitat André T, Boni C, Mounedji-Boudiaf L et al, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351 André T, Boni C, Mounedji-Boudiaf L et al, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351
22.
Zurück zum Zitat Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198–2204CrossRefPubMed Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25:2198–2204CrossRefPubMed
23.
Zurück zum Zitat André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116CrossRefPubMed André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27:3109–3116CrossRefPubMed
24.
Zurück zum Zitat Wolmark N, Wieand S, Kuebler PJ et al (2008) A phase III trial comparing FULV to FULV+oxaliplatin in stage II or III carcinoma of the colon: survival results of NSABP Protocol C-07. Proc Am Soc Clin Oncol 26 (Abstr LBA4005) Wolmark N, Wieand S, Kuebler PJ et al (2008) A phase III trial comparing FULV to FULV+oxaliplatin in stage II or III carcinoma of the colon: survival results of NSABP Protocol C-07. Proc Am Soc Clin Oncol 26 (Abstr LBA4005)
25.
Zurück zum Zitat Haller D, Tabernero J, Maroun J et al (2009) First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). In: Proc ECCO 15–34th ESMO Congr, Berlin, Germany, 20–24 Sept 2009, Abstr 5LBA Haller D, Tabernero J, Maroun J et al (2009) First efficacy findings from a randomized phase III trial of capecitabine + oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). In: Proc ECCO 15–34th ESMO Congr, Berlin, Germany, 20–24 Sept 2009, Abstr 5LBA
26.
Zurück zum Zitat Haller DG, Catalano PJ, Macdonald JS et al (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23:8671–8678CrossRefPubMed Haller DG, Catalano PJ, Macdonald JS et al (2005) Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23:8671–8678CrossRefPubMed
27.
Zurück zum Zitat Scheithauer W, Rosen H, Kornek GV et al (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306:752–755CrossRef Scheithauer W, Rosen H, Kornek GV et al (1993) Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 306:752–755CrossRef
28.
Zurück zum Zitat Simmonds PC (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br Med J 321:531–535CrossRef Simmonds PC (2000) Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. Br Med J 321:531–535CrossRef
29.
Zurück zum Zitat Cunningham D, Pyrhonen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418CrossRefPubMed Cunningham D, Pyrhonen S, James RD et al (1998) Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 352:1413–1418CrossRefPubMed
30.
Zurück zum Zitat de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMed de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMed
31.
Zurück zum Zitat Goldberg R, Sargent D, Morton R et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30CrossRefPubMed Goldberg R, Sargent D, Morton R et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22:23–30CrossRefPubMed
32.
Zurück zum Zitat Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019CrossRefPubMed Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019CrossRefPubMed
33.
Zurück zum Zitat Cassidy J, Clarke S, Díaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012CrossRefPubMed Cassidy J, Clarke S, Díaz-Rubio E et al (2008) Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 26:2006–2012CrossRefPubMed
34.
Zurück zum Zitat Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol 22:229–237CrossRefPubMed Tournigand C, André T, Achille E et al (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR Study. J Clin Oncol 22:229–237CrossRefPubMed
35.
Zurück zum Zitat Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047CrossRefPubMed Douillard JY, Cunningham D, Roth AD et al (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355:1041–1047CrossRefPubMed
36.
Zurück zum Zitat Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779–4786CrossRefPubMed Fuchs CS, Marshall J, Mitchell E et al (2007) Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol 25:4779–4786CrossRefPubMed
37.
Zurück zum Zitat Fuchs CS, Marshall J, Barrueco J et al (2008) Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26:689–690CrossRefPubMed Fuchs CS, Marshall J, Barrueco J et al (2008) Randomized, controlled trial of irinotecan plus infusional, bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol 26:689–690CrossRefPubMed
38.
Zurück zum Zitat Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671CrossRefPubMed Bokemeyer C, Bondarenko I, Makhson A et al (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663–671CrossRefPubMed
39.
Zurück zum Zitat Siena S, Cassidy J, Tabernero J et al (2010) Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. In: Proc 2010 ASCO Gastrointestinal Cancers Symp, Orlando, FL, USA, 22–24 Jan 2010, Abstr 283 Siena S, Cassidy J, Tabernero J et al (2010) Randomized phase III study of panitumumab (pmab) with FOLFOX4 compared to FOLFOX4 alone as first-line treatment (tx) for metastatic colorectal cancer (mCRC): PRIME trial. In: Proc 2010 ASCO Gastrointestinal Cancers Symp, Orlando, FL, USA, 22–24 Jan 2010, Abstr 283
40.
Zurück zum Zitat Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRefPubMed Van Cutsem E, Köhne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417CrossRefPubMed
41.
Zurück zum Zitat Kohne C, Mineur L, Greil R et al (2010) Primary analysis of a phase II study (20060314) combining first-line panitumumab (pmab) with FOLFIRI in the treatment of patients (pts) with metastatic colorectal cancer (mCRC). In: Proc 2010 ASCO Gastrointestinal Cancers Symp, Orlando, FL, USA, 22–24 Jan 2010, Abstr 414 Kohne C, Mineur L, Greil R et al (2010) Primary analysis of a phase II study (20060314) combining first-line panitumumab (pmab) with FOLFIRI in the treatment of patients (pts) with metastatic colorectal cancer (mCRC). In: Proc 2010 ASCO Gastrointestinal Cancers Symp, Orlando, FL, USA, 22–24 Jan 2010, Abstr 414
42.
Zurück zum Zitat Petrelli N, Herrera L, Rustum Y et al (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559–1565PubMed Petrelli N, Herrera L, Rustum Y et al (1987) A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5:1559–1565PubMed
43.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Hainsworth JD et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502–3508CrossRefPubMed Hurwitz H, Fehrenbacher L, Hainsworth JD et al (2005) Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502–3508CrossRefPubMed
44.
Zurück zum Zitat Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65 Kabbinavar F, Hurwitz HI, Fehrenbacher L et al (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21:60–65
45.
Zurück zum Zitat Shirao K, Hoff PM, Ohtsu A et al (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 22:3466–3474CrossRefPubMed Shirao K, Hoff PM, Ohtsu A et al (2004) Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 22:3466–3474CrossRefPubMed
46.
Zurück zum Zitat Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319CrossRefPubMed Sobrero AF, Maurel J, Fehrenbacher L et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311–2319CrossRefPubMed
47.
Zurück zum Zitat Peeters M, Price TJ, Hotko YS et al (2010) Randomized phase III study of panitumumab (pmab) with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): patient-reported outcomes (PRO). In: Proc 2010 ASCO Gastrointestinal Cancers Symp, Orlando, FL, USA, 22–24 Jan 2010, Abstr 282 Peeters M, Price TJ, Hotko YS et al (2010) Randomized phase III study of panitumumab (pmab) with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): patient-reported outcomes (PRO). In: Proc 2010 ASCO Gastrointestinal Cancers Symp, Orlando, FL, USA, 22–24 Jan 2010, Abstr 282
48.
Zurück zum Zitat Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059–2069CrossRefPubMed Rothenberg ML, Oza AM, Bigelow RH et al (2003) Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 21:2059–2069CrossRefPubMed
49.
Zurück zum Zitat Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544CrossRefPubMed Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539–1544CrossRefPubMed
50.
Zurück zum Zitat Rothenberg ML, Cox JV, Butts C et al (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19:1720–1726CrossRefPubMed Rothenberg ML, Cox JV, Butts C et al (2008) Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study. Ann Oncol 19:1720–1726CrossRefPubMed
51.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMed Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337–345CrossRefPubMed
52.
Zurück zum Zitat Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048CrossRefPubMed Jonker DJ, O’Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040–2048CrossRefPubMed
53.
Zurück zum Zitat Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765CrossRefPubMed Karapetis CS, Khambata-Ford S, Jonker DJ et al (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765CrossRefPubMed
54.
Zurück zum Zitat Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664CrossRefPubMed Van Cutsem E, Peeters M, Siena S et al (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658–1664CrossRefPubMed
55.
Zurück zum Zitat Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634CrossRefPubMed Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634CrossRefPubMed
56.
Zurück zum Zitat Skibber JM, Hoff PM, Minsky BD et al (2001) Cancer of the rectum. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, pp 1271–1318 Skibber JM, Hoff PM, Minsky BD et al (2001) Cancer of the rectum. In: Devita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology, 6th edn. Lippincott, Williams and Wilkins, Philadelphia, pp 1271–1318
57.
Zurück zum Zitat Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987 Swedish Rectal Cancer Trial (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 336:980–987
58.
Zurück zum Zitat Camma C, Giunta M, Fiorica F et al (2000) Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. J Am Med Assoc 284:1008–1015CrossRef Camma C, Giunta M, Fiorica F et al (2000) Preoperative radiotherapy for resectable rectal cancer. A meta-analysis. J Am Med Assoc 284:1008–1015CrossRef
59.
Zurück zum Zitat Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 358:1291–1304 Colorectal Cancer Collaborative Group (2001) Adjuvant radiotherapy for rectal cancer: a systematic overview of 22 randomised trials involving 8507 patients. Lancet 358:1291–1304
60.
Zurück zum Zitat Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646CrossRefPubMed Kapiteijn E, Marijnen CA, Nagtegaal ID et al (2001) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345:638–646CrossRefPubMed
61.
Zurück zum Zitat Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701CrossRefPubMed Peeters KC, Marijnen CA, Nagtegaal ID et al (2007) The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 246:693–701CrossRefPubMed
62.
Zurück zum Zitat Marijnen CA, van de Velde CJ, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23:1847–1858CrossRefPubMed Marijnen CA, van de Velde CJ, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23:1847–1858CrossRefPubMed
63.
Zurück zum Zitat Peeters KC, van de Velde CJ, Leer JW et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol 23:6199–6206CrossRefPubMed Peeters KC, van de Velde CJ, Leer JW et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients—a Dutch colorectal cancer group study. J Clin Oncol 23:6199–6206CrossRefPubMed
64.
Zurück zum Zitat Francois Y, Nemoz CJ, Baulieux J et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90–01 randomized trial. J Clin Oncol 17:2396–2402PubMed Francois Y, Nemoz CJ, Baulieux J et al (1999) Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90–01 randomized trial. J Clin Oncol 17:2396–2402PubMed
65.
Zurück zum Zitat Bosset JF, Collette L, Calais G et al, EORTC Radiotherapy Group Trial 22921 (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123 Bosset JF, Collette L, Calais G et al, EORTC Radiotherapy Group Trial 22921 (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123
66.
Zurück zum Zitat Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625CrossRefPubMed Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625CrossRefPubMed
67.
Zurück zum Zitat Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223CrossRefPubMed Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93:1215–1223CrossRefPubMed
68.
Zurück zum Zitat Sauer R, Becker H, Hohenberger W, German Rectal Cancer Study Group et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740 Sauer R, Becker H, Hohenberger W, German Rectal Cancer Study Group et al (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740
69.
Zurück zum Zitat WHO (1990) Cancer pain relief and palliative care (WHO Tech Rep Ser 804). WHO, Geneva, pp 21–22 WHO (1990) Cancer pain relief and palliative care (WHO Tech Rep Ser 804). WHO, Geneva, pp 21–22
70.
Zurück zum Zitat Renehan AG, Egger M, Saunders MP et al (2002) Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trial. Br Med J 324:813–816CrossRef Renehan AG, Egger M, Saunders MP et al (2002) Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trial. Br Med J 324:813–816CrossRef
71.
Zurück zum Zitat Figueredo A, Rumble RB, Maroun J et al (2003) Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 6:26CrossRef Figueredo A, Rumble RB, Maroun J et al (2003) Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer 6:26CrossRef
72.
Zurück zum Zitat Renehan AG, Egger M, Saunders MP et al (2005) Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. Br J Cancer 92:430–433PubMed Renehan AG, Egger M, Saunders MP et al (2005) Mechanisms of improved survival from intensive followup in colorectal cancer: a hypothesis. Br J Cancer 92:430–433PubMed
73.
Zurück zum Zitat Jeffery M, Hickey BE, Hider PN (2007) Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 24:CD002200 Jeffery M, Hickey BE, Hider PN (2007) Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 24:CD002200
74.
Zurück zum Zitat Tjandra JJ, Chan MK (2007) Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 50:1783–1799CrossRefPubMed Tjandra JJ, Chan MK (2007) Follow-up after curative resection of colorectal cancer: a meta-analysis. Dis Colon Rectum 50:1783–1799CrossRefPubMed
75.
Zurück zum Zitat Bruinvels D, Stiggelbout A, Kievit J et al (1994) Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 219:174–182CrossRefPubMed Bruinvels D, Stiggelbout A, Kievit J et al (1994) Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 219:174–182CrossRefPubMed
76.
Zurück zum Zitat Fleischer D, Goldberg S, Browning T et al (1989) Detection and surveillance of colorectal cancer. JAMA 261:580–585CrossRefPubMed Fleischer D, Goldberg S, Browning T et al (1989) Detection and surveillance of colorectal cancer. JAMA 261:580–585CrossRefPubMed
77.
Zurück zum Zitat Green RJ, Metlay JP, Propert K et al (2002) Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Int Med 136:261–269PubMed Green RJ, Metlay JP, Propert K et al (2002) Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Int Med 136:261–269PubMed
78.
Zurück zum Zitat Berman J, Cheung R, Weiberg D (2000) Surveillance after colorectal cancer resection. Lancet 355:395–399CrossRefPubMed Berman J, Cheung R, Weiberg D (2000) Surveillance after colorectal cancer resection. Lancet 355:395–399CrossRefPubMed
79.
Zurück zum Zitat Ueno H, Mochizuki H, Hashiguchi Y et al (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127:385–394CrossRefPubMed Ueno H, Mochizuki H, Hashiguchi Y et al (2004) Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 127:385–394CrossRefPubMed
80.
Zurück zum Zitat Kitajima K, Fujimori T, Fujii S et al (2004) Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 39:534–543CrossRefPubMed Kitajima K, Fujimori T, Fujii S et al (2004) Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 39:534–543CrossRefPubMed
81.
Zurück zum Zitat Tanaka S, Haruma K, Oh-e H et al (2000) Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. Oncol Rep 7:783–788PubMed Tanaka S, Haruma K, Oh-e H et al (2000) Conditions of curability after endoscopic resection for colorectal carcinoma with submucosally massive invasion. Oncol Rep 7:783–788PubMed
82.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum (1980) General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 2nd edn. Kanehara & Co., Ltd., Tokyo Japanese Society for Cancer of the Colon and Rectum (1980) General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 2nd edn. Kanehara & Co., Ltd., Tokyo
83.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum (1994) General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 5th edn. Kanehara & Co., Ltd., Tokyo Japanese Society for Cancer of the Colon and Rectum (1994) General rules for clinical and pathological studies on cancer of the colon, rectum and anus, 5th edn. Kanehara & Co., Ltd., Tokyo
84.
Zurück zum Zitat Japanese Society for Cancer of the Colon and Rectum (2005) JSCCR guidelines 2005 for the treatment of colorectal cancer. Kanehara & Co., Ltd., Tokyo Japanese Society for Cancer of the Colon and Rectum (2005) JSCCR guidelines 2005 for the treatment of colorectal cancer. Kanehara & Co., Ltd., Tokyo
85.
Zurück zum Zitat Cappuzzo F, Finocchiaro G, Rossi E et al (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19:717–723CrossRefPubMed Cappuzzo F, Finocchiaro G, Rossi E et al (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19:717–723CrossRefPubMed
86.
Zurück zum Zitat Lièvre A, Bachet JB, Boige V et al (2008) KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374–379CrossRefPubMed Lièvre A, Bachet JB, Boige V et al (2008) KRAS mutation as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374–379CrossRefPubMed
87.
Zurück zum Zitat Lièvre A, Bachet JB, Corre DL et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995 Lièvre A, Bachet JB, Corre DL et al (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66:3992–3995
88.
Zurück zum Zitat Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230–3237CrossRefPubMed Khambata-Ford S, Garrett CR, Meropol NJ et al (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230–3237CrossRefPubMed
89.
Zurück zum Zitat de Reyniès A, Boige V, Milano G et al (2007) KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol 26:2228–2230 de Reyniès A, Boige V, Milano G et al (2007) KRAS mutation signature in colorectal tumors significantly overlaps with the cetuximab response signature. J Clin Oncol 26:2228–2230
90.
Zurück zum Zitat Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166–1169 Di Fiore F, Blanchard F, Charbonnier F et al (2007) Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by cetuximab plus chemotherapy. Br J Cancer 96:1166–1169
91.
Zurück zum Zitat Wierzbicki R, Jonker DJ, Moore MJ et al (2009) A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs 23:1803–1810 Wierzbicki R, Jonker DJ, Moore MJ et al (2009) A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining. Invest New Drugs 23:1803–1810
Metadaten
Titel
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer
verfasst von
Toshiaki Watanabe
Michio Itabashi
Yasuhiro Shimada
Shinji Tanaka
Yoshinori Ito
Yoichi Ajioka
Tetsuya Hamaguchi
Ichinosuke Hyodo
Masahiro Igarashi
Hideyuki Ishida
Megumi Ishiguro
Yukihide Kanemitsu
Norihiro Kokudo
Kei Muro
Atsushi Ochiai
Masahiko Oguchi
Yasuo Ohkura
Yutaka Saito
Yoshiharu Sakai
Hideki Ueno
Takayuki Yoshino
Takahiro Fujimori
Nobuo Koinuma
Takayuki Morita
Genichi Nishimura
Yuh Sakata
Keiichi Takahashi
Hiroya Takiuchi
Osamu Tsuruta
Toshiharu Yamaguchi
Masahiro Yoshida
Naohiko Yamaguchi
Kenjiro Kotake
Kenichi Sugihara
Japanese Society for Cancer of the Colon and Rectum
Publikationsdatum
01.02.2012
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 1/2012
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0315-2

Weitere Artikel der Ausgabe 1/2012

International Journal of Clinical Oncology 1/2012 Zur Ausgabe

Introduction to Review Articles

Early mesothelioma revisited

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.